Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • News
    • pharma-news

    pharma-news - Page 78

    Johnson and Johnson wins EMA vote for depression drug Spravato

    Johnson and Johnson wins EMA vote for depression drug Spravato

    Medical Dialogues Bureau21 Oct 2019 10:15 AM IST
    J&J has said that over 2,000 centres in the U.S. have been certified to administer Spravato, which has been touted as an asset with blockbuster...
    Granules India gets USFDA nod for Fexofenadine Hydrochloride tablets to treat allergy symptoms

    Granules India gets USFDA nod for Fexofenadine Hydrochloride tablets to treat allergy symptoms

    Farhat Nasim21 Oct 2019 10:00 AM IST
    Granules India's Fexofenadine Hydrochloride tablets USP is bio-equivalent to the reference listed drug product (RLD), Allegra Allergy Tablets, 60 mg...
    Sanofi pulls popular heartburn drug Zantac in US, Canada

    Sanofi pulls popular heartburn drug Zantac in US, Canada

    Medical Dialogues Bureau21 Oct 2019 9:30 AM IST
    In September, the Food and Drug Administration said a potentially cancer-causing chemical had been detected at low levels in prescription and...
    Landmark trial expected after opioid settlement talks fail

    Landmark trial expected after opioid settlement talks fail

    Medical Dialogues Bureau21 Oct 2019 9:00 AM IST
    New Delhi: A landmark trial over the U.S. opioid epidemic is on track to begin on Monday after drug companies and local governments failed to agree on...
    AstraZeneca, Daiichi Trastuzumab deruxtecan gets USFDA priority review for treating breast cancer

    AstraZeneca, Daiichi Trastuzumab deruxtecan gets USFDA priority review for treating breast cancer

    Medical Dialogues Bureau20 Oct 2019 9:50 AM IST
    New Delhi: AstraZeneca and Daiichi Sankyo Company, Limited (Daiichi Sankyo) recently announced that the US Food and Drug Administration (FDA) has...
    Novartis Jakavi meets primary endpoint in study of acute graft-versus-host disease

    Novartis Jakavi meets primary endpoint in study of acute graft-versus-host disease

    Medical Dialogues Bureau20 Oct 2019 9:35 AM IST
    New Delhi: Novartis recently announced positive topline results from the Phase III REACH2 study evaluating Jakavi (ruxolitinib) in patients with...
    Boehringer Ingelheim enrolls patients in Phase 2 trial of cystic fibrosis treatment

    Boehringer Ingelheim enrolls patients in Phase 2 trial of cystic fibrosis treatment

    Medical Dialogues Bureau20 Oct 2019 9:30 AM IST
    New Delhi: Boehringer Ingelheim recently announced the first patient enrolled in its Phase II clinical trial BALANCE-CF to evaluate a new potential...
    Five drug firms, distributors offer to settle US opioid suits with USD 50 billion package: Report

    Five drug firms, distributors offer to settle US opioid suits with USD 50 billion package: Report

    Medical Dialogues Bureau20 Oct 2019 9:00 AM IST
    Distributors McKesson Corp, Amerisource Bergen Corp and Cardinal Health have offered to pay $18 billion in cash over 18 years, while drugmaker Johnson...
    USFDA alerts iconic Johnsons Baby Powder contaminated with Asbestos

    USFDA alerts iconic Johnsons Baby Powder contaminated with Asbestos

    Medical Dialogues Bureau19 Oct 2019 12:34 PM IST
    The move marks the first time the company has recalled its iconic baby powder for possible asbestos contamination, and the first time U.S. regulators...
    Lupin largest, most advanced oral solid dosage facility gets EIR from USFDA

    Lupin largest, most advanced oral solid dosage facility gets EIR from USFDA

    Medical Dialogues Bureau19 Oct 2019 11:16 AM IST
    The inspection for the oral solid facility at Nagpur closed without any Form 483 observation. The Nagpur facility is Lupin Ltd’s largest and most...
    Indoco Remedies successfully clears USFDA inspection of CRO facility AnaCipher

    Indoco Remedies successfully clears USFDA inspection of CRO facility AnaCipher

    Medical Dialogues Bureau19 Oct 2019 11:05 AM IST
    Commenting on this development, Aditi Kare Panandikar, Managing Director, Indoco Remedies Limited said, “This achievement is for the fifth time in a...
    Merck gets European nod for Ebola vaccine Ervebo

    Merck gets European nod for Ebola vaccine Ervebo

    Medical Dialogues Bureau19 Oct 2019 9:15 AM IST
    The European Medicines Agency (EMA) said its human medicines committee (CHMP) has recommended granting conditional marketing authorization in the...
    PrevNext

    Popular Stories

    FDC Ban: Supreme Court Relief to Saridon, Piriton and Dart

    FDC Ban: Supreme Court Relief to Saridon, Piriton and Dart

    Ayurvedic Medicines for Blood Sugar, Diet containing Metformin Hydrochloride: Ayurveda Firm Booked

    Ayurvedic Medicines for Blood Sugar, Diet containing Metformin Hydrochloride: Ayurveda Firm Booked

    Union Pharma Secretary Holds video conference with Pharma manufacturers and associations, takes feedback

    Union Pharma Secretary Holds video conference with Pharma manufacturers and associations, takes...

    Rising prices of hydroxychloroquine raw material forces small scale pharmas in Haridwar to stop production

    Rising prices of hydroxychloroquine raw material forces small scale pharmas in Haridwar to stop...

    Owner of BLK Hospital, Radiant Life care looks to buy Max Healthcare stake

    Owner of BLK Hospital, Radiant Life care looks to buy Max Healthcare stake

    Novartis Expiry of Patent for Blockbuster Vildagliptin to Clear Way for Competitors

    Novartis Expiry of Patent for Blockbuster Vildagliptin to Clear Way for Competitors

    Top priority on Delivery of Medicines through Speed Post: Minister

    Top priority on Delivery of Medicines through Speed Post: Minister

    French court dismisses damage claims against Merck over Levothyrox

    French court dismisses damage claims against Merck over Levothyrox

    View All

    • Email: info@medicaldialogues.in
    • Phone: 011 - 4372 0751

    Website Last Updated On : 13 Oct 2022 5:14 AM GMT
    Company
    • About Us
    • Contact Us
    • Our Team
    • Reach our Editor
    • Feedback
    • Submit Article
    Ads & Legal
    • Advertise
    • Advertise Policy
    • Terms and Conditions
    • Privacy Policy
    • Editorial Policy
    • Comments Policy
    • Disclamier
    Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

    Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

    © 2025 - Medical Dialogues. All Rights Reserved.
    Powered By: Hocalwire
    X
    We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok